Clinical Trial Update: Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline [Phase 4]

View source ↗

Summary

Phase 4 trial results examine how Florbetapir (18F) PET imaging changes patient management in Alzheimer's disease and explore the relationship between scan stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Amyvid (florbetapir F-18) (florbetapir)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2016-08-17